Passage Bio Q2 2026 Earnings Report

Passage Bio EPS Results

• Actual EPS: N/A
• Consensus EPS: -$2.27
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Passage Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Passage Bio Announcement Details

• Quarter: Q2 2026
• Date: 8/3/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 7, 2026
• Conference Call Time: 9:30AM ET

Passage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit. Passage Bio is also advancing PBFT02, an AAV-based gene therapy targeting progranulin deficiency in frontotemporal dementia linked to GRN mutations, and PBCH10 for achromatopsia, a rare inherited form of color blindness. Each program is designed to address significant unmet needs in genetically defined patient populations.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Passage Bio emerged from collaborations with academic and research institutions specializing in gene therapy and neurology. The company completed its initial public offering in 2020 to support clinical development and expand manufacturing capabilities. Its leadership team is led by President and Chief Executive Officer David Meeker, who brings extensive experience in biotechnology and rare disease drug development.

Passage Bio conducts its clinical and preclinical activities primarily in the United States and collaborates with international research centers to facilitate patient access and data collection. The company is committed to advancing transformational therapies for patients with severe genetic disorders and strengthening its vector manufacturing infrastructure to ensure scalable and compliant production.